Takeda's Entyvio associated with clinical benefits for IBD patients: 3 study insights

Long-term use of Takeda Pharmaceutical's Entyvio (vedolizumab) may improve quality of life for patients suffering from inflammatory bowel disease, according to two interim reports published in the Journal of Crohn’s and Colitis.

The reports discuss interim findings from an ongoing phase III extension study, which evaluates the safety of long-term vedolizumab treatment on patients with ulcerative colitis and Crohn's disease. The data for these interim reports was collected between May 22, 2009 and June 27, 2013.

Here's what you need to know:

1. The reports include outcomes of clinical response, remission and health-related quality of life factors, which were assessed for up to 152 weeks of treatment.

2. Patients with moderately to severely active ulcerative colitis reported clinical and health-related quality of life improvements with long-term vedolizumab treatment.

3. Patients with moderately to severely active Crohn's disease reported clinical benefits with long-term vedolizumab treatment, regardless of prior tumor necrosis factor antagonist exposure.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast